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Objectives/Hypothesis: Although many proin-
flammatory cytokines have been identified in nasal
polyp tissue, the initial trigger that causes this
inflammation characterized by edema, lymphocytosis,
and eosinophilia, is still unknown. The purpose of the
present study is to identify the presence of genetic
polymorphisms in proinflammatory, anti-inflamma-
tory, and chemokine genes that might contribute to
genetic susceptibility to chronic hyperplastic sinusitis
with nasal polyposis (CHSwNP).
Study Design: Case control study.
Methods: Buccal swabs were taken from the left
and right oral mucosal surfaces from 179 patients
with CHSwNP and 153 nonpolyposis controls with
the Purgene DNA purification protocol (Gentra). Gen-
otyping assays for cytokine gene loci were performed
on 14 cytokine genes using the iPlex Gold and the
Mass Array Compact system (Sequenom, San Diego,
CA). Tests of Hardy-Weinberg equilibrium proportions
were performed separately in the cases and controls.
Tests for evidence of association between alleles at
each single-nucleotide polymorphism (SNP) and case-
control status were performed using unconditional
logistic regression.
Results: The frequency of the A allele in a SNP
located in tumor necrosis factor (TNF)-a (rs1800629)
is significantly different in patients with nasal poly-
posis versus controls without nasal polyposis, 18.6%
and 11.5%, respectively with an individuals’ odds of
susceptibility to nasal polyps increasing almost two-
fold (odds ratio, 1.86; confidence interval, 1.4–3.09)
given at least one copy of the A allele at this SNP. All
other cytokine gene polymorphisms of both inflamma-
tory, anti-inflammatory, and chemokine genes were
not statistically different between the two groups.
Conclusions: TNF-a-308, a SNP in the pro-
moter region of this cytokine gene is associated with
increased odds of developing nasal polyposis. TNF-a
is a potent immuno-mediator and proinflammatory
cytokine that has been implicated in the pathogenesis
of a large number of human diseases. The location of
this gene on the short arm of chromosome 6, with the
major histocompatibility complex genes and comple-
ment, has raised the probability that polymorphism
within this locus may contribute to a genetic associa-
tion of this region of the genome with a wide variety
of infectious and autoimmune diseases.
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A growing body of evidence is mounting to suggest
that much of the host response to infectious disease is a
direct reflection of heritable traits, accounting for inter-
personal differences, and allowing for genetic detection.1
The role of the innate and acquired immune response in
chronic inflammatory diseases is regulated and sus-
tained by the activation of an acquired immune response
to antigen-presenting cells, such as macrophages and
dendritic cells with the subsequent release of inflamma-
tory mediators.2 The inflammatory response is sustained
by the overproduction of inflammatory mediators of
T-lymphocytes and macrophage-derived cytokines.
When these mediators are produced in excess, or
when their counteracting receptor antagonists or antago-
nistic-binding proteins are deficient, the protective role
of the immune system devolves into a harmful one capa-
ble of tissue injury in the host.3
It is now clear that chronic hyperplastic sinusitis
with nasal polyposis (CHSwNP) is a chronic inflamma-
tory disease, in which proinflammatory cytokines play a
major role.4 In an effort to understand the mechanisms
of this disorder and to develop new therapeutic strat-
egies, specific biochemical mediators and cytokines
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involved in CHSwNP, as well as their genetic control
have been targeted.5
The genetic predisposition of patients who develop
CHSwNP following exposure to bacteria, fungus, allergy,
virus, or traumatic insult has only begun to be explored
experimentally. If a relationship between the genetic
constitution of a patient as a response to a major inflam-
matory stimulus could be established, better injury-
scoring systems could be devised that more accurately
predict the clinical trajectory of a patient. Whether or
not the triggering events are microbial, fungal, or aller-
gic products, the key initiators of the inflammatory
responses are cytokines.
Areas of variability, called polymorphisms within a
gene, are stable. Strictly defined, a polymorphism is the
existence of two or more sequence variances occurring at
significant frequencies within a population. The most
common example is a single-nucleotide polymorphism
(SNP). SNPs are single nucleotides that are substituted
for other nucleotides within a sequence of the allele.
Certain polymorphisms, in either the promoter or
core region of a gene, may be associated with such
chronic inflammatory diseases as periodontitis, inflam-
matory bowel disease, cancer, septic shock, otitis media,
and other inflammatory diseases.6–10 At the present
time, several investigations have reported an association
between nasal polyposis and SNPs of proinflammatory
cytokine genes.11–15 These reported investigations have
looked at susceptibility to nasal polyposis measuring one
or two single polymorphisms.
We sought to investigate the role of seven proin-
flammatory, four anti-inflammatory, one Toll receptor,
and two chemokine polymorphisms in patients with
massive nasal polyposis previously shown to be associ-
ated with chronic inflammation.
MATERIALS AND METHODS
Study Population
Buccal swabs were obtained from 332 participants (179
patients with CHSwNP and 153 control patients). The control
patients did not have a history of rhinosinusitis, chronic peri-
odontal disease, inflammatory bowel disease, cancer, sepsis, or
otitis media or any other chronic inflammatory disorder. Sinus
cases were selected on the basis of a diagnosis of CHSwNP. The
study was approved by the institutional review board of the
State University of New York at Buffalo, and all patients con-
sented at the time the buccal sample was taken. Demographic
summary statistics for the total population, the cases only, and
the controls only were calculated. The swabs were inserted into
normal saline and frozen until SNP genotyping.
Selection of Patients
The subject patients all had chronic hyperplastic sinusitis
with nasal polyposis. On clinical examination, all patients had
visible nasal polyps with the unaided eye. Ninety-eight percent
of these patients had bilateral disease, and 2% had unilateral
disease. Using the scoring system of Gaskins16 for the extent of
polyposis, all patients were in the classification of two or three,
indicating that the nasal polyps were well below the middle tur-
binate and some almost extending toward the external nares.
In regard to radiological score, the patients had a mean score of
greater than 12 (Lund-MacKay),17 indicating bilateral opacifica-
tion of the anterior and posterior ethmoids, and bilateral
opacification of maxillary sinuses and obliteration of the infun-
dibulum bilaterally.
The diagnosis of allergy was made by intradermal dilu-
tional testing.
The presence of acetylsalicylic acid (ASA) intolerance was
made primarily by history, in which the patients were told by
their allergists or pulmonologists that they were not to take
any aspirin product for fear of the development of severe
asthma. Therefore, the majority of patients gave a history of as-
pirin intolerance and had a combination of asthma and chronic
hyperplastic sinusitis with nasal polyposis.
SNP Selection and Genotyping
SNP genotyping of 14 markers that have been documented
in the literature to play a role in chronic inflammation was per-
formed using iPLEX Gold and the MassARRAY Compact
system (Sequenom, San Diego, CA).18 Polymerase chain reac-
tion (PCR) primers are summarized in Table I.
DNA was extracted from buccal cells of 179 polyposis
patients and 153 controls with the Puregene DNA purification
protocol (Gentra Systems, Inc., Minneapolis, MN). All SNP spe-
cific and mass extended oligonucleotides were designed using
RealSNP and MassARRAY Assay Designer (Sequenom).18 Five
nanograms of DNA were added to each 5-lL PCR reaction
mixture in 384-W plates. PCR primers were assigned into
appropriate multiplex groups by RealSNP and used at a 200 ng
final concentration. Genotype confidence scores of conservative
(A), moderate (B), and aggressive (C) were used for analysis
and evaluated for quality. Genotype confidence scores below C
were not included in the analysis.
Statistical Analyses
Using Fisher exact test, each SNP was tested to determine
if the population under investigation showed deviation from ge-
notype frequencies expected under Hardy-Weinberg equilibrium
(HWE) proportions.19 Tests were performed separately in the
cases and controls. Tests for evidence of association between
alleles at each SNP and case-control status were performed
using unconditional logistic regression.20,21 Specifically, we
tested whether carriers of each genotyped SNP have different
risk than noncarriers (0 copies) by testing for independence in
2  3 tables using standard odds ratio analysis using a test for
trend. Covariates age and sex (all patients were self-identified
Caucasians and thus race specific analyses were not performed)
were only included in the final model if they were found to
increase the odds of disease, increase/decrease the effect of the
allele, or other covariates by at least 10%.
RESULTS
Study Participants
Demographic characteristics of the population are
presented in Table II. The 179 cases (110 males and 69
females) ranged in age from 18 years to 87 years, with a
mean (standard deviation [SD]) age of 55.4 (15.6) years.
The 153 controls (49 males and 104 females) ranged in
age from 12 years to 86 years, with a mean (SD) age of
46.5 (14.04) years. The median age of the cases and
controls was 54 and 50, respectively.
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Genetic Analyses
The genotyping call rate for each SNP ranged from
83% to 96%, with an average call rate of 93%. Eleven of
the 14 SNPs genotyped were in HWE proportions in the
control population. Two SNPs, rs3087258 (IL-1b-511)
and rs1800894 (IL-10-819), showed significant (P < .01)
deviation from HWE proportions; one SNP, rs1344735
(IL-6) was monomorphic (e.g., one only copy of the allele
was present). These three SNPs were eliminated from
the analysis.
The frequency of the A allele in a SNP located in
tumor necrosis factor (TNF)-a (rs1800629) is signifi-
cantly different in patients with nasal polyposis versus
controls without nasal polyposis, 18.6% and 11.5%,
respectively, with an individuals’ odds of susceptibility to
nasal polyps increasing almost two-fold (odds ratio, 1.86;
confidence interval, 1.14–3.09) given at least one copy of
the A allele at this SNP (Table III). We did not find
statistically significant results for any other SNPs eval-
uated. The multiple SNPs tested on chromosome 1 or
chromosome 2 were not in pairwise linkage disequili-
brium with one another.
An analysis of the A allele at position 308 of
the TNF-a gene in the polyp patients was not signifi-
cantly different in regard to gender, allergy, or ASA
intolerance.
DISCUSSION
Our results suggest that the frequency of the A
allele, whether homozygous or heterozygous in the 308
position of the promoter region of the cytokine gene
TNF-a, is significantly higher in patients with nasal pol-
yposis than in control patients. The A allele in this
position of the TNF-a gene is associated with increased
transcription of the protein TNF-a.22,23 These findings
would then support the concept that this polymorphism
has direct effect on TNF-a gene regulation and possibly
lead to more severe disease in patients with CHSwNP.
Table II demonstrates a significant difference in the
number of male patients having nasal polyposis com-
pared with female patients. This difference is about 2:1
in favor of male patients having nasal polyposis in this
study.
There has been support for this male to female pre-
dominance for nasal polyposis in the literature. Collins
et al.24 reported similar findings in regard to gender in
nasal polyposis. They suggested that males were more
commonly smokers and had more occupational exposure
to dust and chemicals in comparison to females. Busaba
et al.25 demonstrated no statistically significant differ-
ence in regard to environmental allergy, asthma,
psychiatric illness, or anatomical variance comparing
the genders in chronic rhinosinusitis. However, chronic
rhinosinusitis without polyposis was more commonly
diagnosed among women, whereas chronic rhinosinusitis
with polyposis was more commonly diagnosed among
men (P < .05).
TNF-a is produced primarily but not exclusively by
macrophages and T cells, respectively.26,27 Initially, iden-
tified for its cytotoxic and antitumor activity, it is now
well-documented that this cytokine plays a critical role
in a variety of immunological processes, including
inflammation, secondary lymphoid organ development,
and the control of intracellular pathogens.28 The TNF
locus is located in the class 3 region of the human major
histocompatibility complex on the short arm of chromo-
some 6 (Fig. 1). These genes include the HLA A, B, and
C, HLA DR, DQ, and DP loci, which collectively have
been called immune response genes. Because these
genes are close together, they are usually transmitted
from generation to generation in linkage disequilibrium;
that is, they are almost always transferred from parent
to child together. Whether or not the TNF-a polymor-
phisms themselves play a role in susceptibility to
disease, or they are in linkage disequilibrium with other
immune response genes close by, is not yet completely
known.
Previous investigations on genetic polymorphisms
in nasal polyposis have been reported.11–15 Karjalainen
and collaborators in Finland described the IL1A geno-
type as being associated with nasal polyposis in
asthmatic adults.11 They analyzed the single G to T base
exchange polymorphism in exon 5 at þ4845 of the gene
encoding IL1-a. The distribution of IL1-a genotype dif-
fered significantly between asthmatics with or without
nasal polyps. The risk of nasal polyps was markedly
increased in patients with the G homozygous allele sub-
jects. Cheng et al.12 at National Taiwan University
described the association of interleukin 1B and interleu-
kin 1 receptor antagonists (IL-1Ra) gene polymorphisms
and chronic sinusitis. The authors demonstrated an
increased prevalence of IL1Ra polymorphism in patients
with chronic rhinosinusitis suggesting that this polymor-
phism, or a polymorphism in linkage disequilibrium
with it, may be involved in the susceptibility to chronic
rhinosinusitis. Of the 88 patients in this group, almost
80% were diagnosed as having nasal polyposis. These
investigators did not study TNF-a.
TABLE II.









Female 171 (51.4%) 69 (36.8%) 102 (68.0%)
Male 161 (48.6%) 110 (63.2%) 51 (32.0%)
Allergies
No 178 (53.5%) 53 (29.6%) 125 (81.7%)
Yes 154 (46.5%) 126 (70.4%) 28 (18.3%)
Asthma
No 259 (78.5%) 109 (61.6%) 150 (98.0%)
Yes 73 (21.5%) 70 (38.4%) 3 (2.0%)
ASA intolerance
No 299 (90.0%) 148 (83.6%) 151 (98.7%)
Yes 33 (10.0%) 31 (16.4%) 2 (1.3%)
ASA ¼ acetylsalicylic acid.
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Erbeck and collaborators13 in Turkey reported IL-
1A (þ4845 GT and þ4845 TT), IL-1B (511 CC), and
TNF-a (238 AA and 308 GA) genotypes to be associ-
ated with nasal polyposis. They found that the GG
homozygous haplotype was associated more with
controls than with patients with nasal polyps. An unex-
pected finding in their report was that homozygous A
genotype was much more common in controls than in
cases. This is unexpected inasmuch as all reports in the
literature thus far have suggested that the AA homozy-
gous genotype is both very rare, and is always
associated with the highest transcription of TNF-a, and
therefore associated with chronic inflammatory disease
in the great majority of patients. They do not explain
this high incidence of homozygous AA in their control
group for TNF-a 308.
Studies have described polymorphisms in genes
involved with both leukotriene synthesis and remodeling
in chronic hyperplastic sinusitis with nasal polyposis.14
Wang et al.15 studied the matrix metalloproteinase-
2 (MMP2) gene polymorphisms in nasal polyps. They
concluded the MMP2 gene does not play a crucial role in
conferring risk for nasal polyps in a Taiwanese
population.
One important aspect that was not investigated in
all but the last two studies was HWE proportions.
Broadly, significant deviation in the cases can actually
buttress evidence of association, indicating possibly
selective pressure in that genomic region under investi-
gation; however, violations in HWE proportions in the
control population indicate that the controls might
actually not be an appropriate control population. Thus,
both cases and controls should be tested separately for
evidence of violation of HWE proportions. The impact of
not considering HWE proportions in genetic association
studies was investigated in a meta-analysis of almost 50
studies.19
Exclusion of the violating studies resulted in loss of
statistical significance of this overall meta-analysis in
three instances and more than a 10% change in the
summary odds ratio in six. Thus, clearly for accuracy
and particularly replication purposes, HWE proportions
as well as nonsignificant deviations from the exact fre-
quencies expected under HWE proportions in gene-
disease association studies should be carefully consid-
ered. We reviewed the genotype distributions presented
TABLE III.
Statistical Analysis of SNP.
Gene Symbol (Location) SNP Chr Position in Base Pairs From Chr Start Alleles HWE P Value* OR (CI) OR P Value
IL-10 (592) rs1800895 1 205013095 A/G .87 † †
IL-10 (819) rs1800894 1 205013289 A/G .0009 † †
IL-10 (1082) rs1800896 1 205013520 A/G .64 † †
IL-1a (þ4845) rs17561 2 113253694 G/T .51 † †
IL-1a (819) rs3783521 2 113260048 C/T .38 † †
IL-b (þ3935) rs1143634 2 113306861 C/T .73 † †
IL-b (511) rs3087258 2 113311342 C/T .0001 † †
CD14 (159) rs2569190 5 139993100 A/G .16 † †
TNF-a (308) rs1800629 6 31651010 A‡/G .93 1.86 (1.14,3.09)§ .01
IL-6 (174) rs13447445 7 22733281 C/G || † †
IFNc (874) rs2430561 12 66838789 A/T .71 † †
CCL2 (2518) rs3917882 17 29603912 A/G .93 † †
CCL5 (403) rs2107538 17 31231893 C/T .81 † †
TGF-b1 (509) rs11466315 19 46551616 C/G .86 † †
SNP ¼ single-nucleotide polymorphism; Chr ¼ chromosome; HWE ¼ Hardy Weinberg equilibrium; OR ¼ odds ratio; CI ¼ confidence interval; rs ¼ refer-
ence SNP; IL ¼ interleukin; TNF ¼ tumor necrosis factor; IFN ¼ interferon; TGF ¼ transforming growth factor; CCL ¼ cysteinyl chemokine ligand.
*Fisher exact test P values for tests of Hardy Weinberg equilibrium proportions in controls.




Fig. 1. Short arm of chromosome 6 demonstrating position of HLA
antigens and some complement components and TNF-a and
other inflammatory proteins. These genes are transmitted from
generation to generation in genetic disequilibrium.
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in the five studies previously mentioned and tested the
controls for violations of HWE proportions. HWE propor-
tions were violated in the significant SNPs in two
studies.11,13 These violations should be carefully consid-
ered when evaluating the evidence for genetic
association with CHSwNP.
The mechanism by which lymphocytes and espe-
cially eosinophils migrate into the epithelium and
lamina propria of nasal polyps is now becoming unrav-
eled. Our knowledge of the trafficking of these cells from
the bloodstream to the nasal mucosa via the cell surface
receptors on inflammatory cells and their counter recep-
tors on the venules of nasal mucosal tissue has been
established. TNF-a and IL1-b, two potent proinflamma-
tory cytokines, known to be upregulated in nasal polyps,
appear to be responsible for this trafficking and migra-
tion of inflammatory cells into the nasal polyps. The
mechanisms by which this takes place have been
elucidated.29,30
TNF-a upregulates VCAM-1 and NF-jB in fibro-
blasts from nasal polyps.29 Nasal fibroblasts produce
VCAM-1, and that production is increased by TNF-a
stimulation. VCAM-1 expression in nasal fibroblasts is
induced through an NF-jB dependent pathway. These
findings might provide a rationale for using NF-jB
inhibitors as a treatment for nasal inflammation.
The receptor on the surface of lymphocytes and eo-
sinophils, which migrate to these counter receptors on
endothelial venules, have also been established to
be very late antigen 4, either a-4 b-1 or a-4 b-7. Our
laboratory has established that both VCAM-1 in
the endothelium of nasal polyps, as well as VLA-4 on
the surface of eosinophils, are present in nasal
polyposis.4
In summary, the increased transcription of TNF-a
in the cells of nasal polyps can increase integrins on the
surface of eosinophils and lymphocytes in the polyp tis-
sue, but also increase the counter receptor VCAM-1 on
the endothelium, thus, driving the eosinophils into the
polypoid tissue. The eosinophils that have accumulated
in the tissue of the polyp can also synthesize and release
TNF-a. By using southern blot analysis after a reverse
transcription-PCR., Finotto and colleagues31 detected a
signal specific for TNF-a mRNA in nasal polyp eosino-
phils. Thus an autocrine up-regulation of eosinophils
may occur in the nasal polyp. Eosinophils that arrive
in the nasal polyp tissue may then synthesize TNF-a,
which subsequently recruit more eosinophils and,
thus, a chronic inflammatory disorder, in which eosino-
phils and lymphocytes predominate emerges in
CHSwNP.
Finally, TNF-a can also increase the secretion of
chemokines that attract eosinophils into the nasal polyp
mucosa. Not only does TNF-a increase the secretion of
eotaxin,32 but it can also increase the expression of
RANTES (regulated on activation, normal T cell
expressed and secreted) from polyp fibroblasts.33 Thus,
there is evidence that TNF-a increases the secretion of
chemokines that attract eosinophils into the nasal polyp
from constitutive cells that are present, such as
fibroblasts.
CONCLUSION
We found that allelic frequencies at the promoter
region of the cytokine gene TNF-a at the locus 308
were significantly different in patients with massive
nasal polyposis compared to healthy controls, and that
patients with the A allele at this locus showed an
increased susceptibility to disease. This finding coupled
with the fact that the presence of the A allele at this
SNP is associated with higher secretion rates for this
proinflammatory cytokine provides plausible evidence
that this locus is in the casual disease pathway. The
rational for this is as follows. If the levels of TNF-a are
increased in the nasal polyp tissue (as with the presence
of the A allele), a programmed sequence of events occurs
that includes; 1) upregulation of the integrins on the
surface of eosinophils; 2) increased synthesis of the coun-
ter receptor for these integrins on the endothelia of
venules, namely, VCAM-1; the increased integrins on
eosinophils and the counter receptor VCAM-1 allow
eosinophils to migrate into the polyp lamina propria;
3) the eosinophils may then secrete more TNF-a, which
recruits more eosinophils; and 4) TNF-a also may be re-
sponsible for increasing the synthesis and release of the
chemokines RANTES and eotaxin from structural cells,
namely fibroblasts, in the nasal polyp, which recruit
even more eosinophils.
In conclusion, the A allele in the promoter region of
the TNF-a gene at position 308 leads to an increase in
the production of TNF-a and a cascade of events that
yield increased susceptibility to developing CHSwNP.
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